RBC Capital Markets reiterated their outperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research note published on Monday. RBC Capital Markets currently has a $108.00 price objective on the stock.

Several other analysts have also recently issued reports on SRPT. Vetr upgraded shares of Sarepta Therapeutics from a sell rating to a hold rating and set a $17.28 target price on the stock in a research note on Monday, June 20th. Oppenheimer Holdings Inc. reiterated an outperform rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, June 21st. Wedbush reiterated an outperform rating and issued a $36.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, June 22nd. Jefferies Group reiterated an underperform rating and issued a $7.00 target price on shares of Sarepta Therapeutics in a research note on Saturday, June 25th. Finally, William Blair reiterated a market perform rating on shares of Sarepta Therapeutics in a research note on Monday, June 27th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics has an average rating of Buy and an average target price of $63.54.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 3.016% on Monday, reaching $50.416. 807,169 shares of the company were exchanged. The stock’s market capitalization is $2.41 billion. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The firm has a 50 day moving average price of $45.66 and a 200-day moving average price of $26.92.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm posted ($0.87) EPS. On average, analysts predict that Sarepta Therapeutics will post ($4.23) EPS for the current fiscal year.

In related news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP David T. Howton sold 7,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $420,000.00. Following the transaction, the senior vice president now directly owns 28,453 shares of the company’s stock, valued at $1,707,180. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Fund Advisors boosted its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the period. State Street Corp boosted its position in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares during the period. Commonwealth Equity Services Inc acquired a new position in shares of Sarepta Therapeutics during the second quarter worth about $302,000. National Planning Corp boosted its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares during the period. 65.06% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.